Whoever saves a life it will be as if he or she has saved the whole of humanity. (Al Quran 5:32/33)
FRANKFURT (Reuters) – Biotech firm BioNTech said on Monday it widened an ongoing pivotal global study of its COVID-19 vaccine candidate to include testing in its home country of Germany.
Germany’s vaccines regulator, the Paul Ehrlich Institute, gave the approval for the Phase 2/3 trial of the experimental vaccine known as BNT162b2, BioNTech and its partner Pfizer said in a statement.
The global trial was initiated in July, with a view to including about 120 sites globally and seeking up to 30,000 participants in total.
More than 25,000 participants have been enrolled, BioNTech said, adding it remained on track to seek approval for BNT162b2 as early as next month.
The best of the Muslim Times’ collection for war against Covid 19:
In this day and age, understanding bacteria and viruses and developing vaccines are national security issues. In my view sizable part of every country’s defense budget should be spent in these pursuits rather than making tanks and other weapons.
For the latest news about drugs and vaccines’ trials please go to: Pharmaceutical-Technology
For the latest health news from BBC, Please click here
The Muslim Times has the best collections in the war against Covid 19 as we are collecting from all the established sources
For the number of cases and epidemiology in each country go to: WorldOMeters
DAILY NEW CASES AND DEATHS IN US, CDC SITE